Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

@article{Brodowicz2006CisplatinAG,
  title={Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.},
  author={Thomas Brodowicz and Maciej Jerzy Krzakowski and Matjaz Zwitter and Valentina Tzekova and Rodryg Adam Ramlau and Nicolae Ghilezan and Tudor Ciuleanu and Branka {\vC}u{\vc}evi{\'c} and K{\'a}lm{\'a}n Gyurkovits and Ernst Ulsperger and Jacek Jassem and Mislav Grgic and Pinar Saip and M{\'a}ria Szilasi and Christoph Wiltschke and Maria Wagnerova and Natalya Oskina and Victoria O. Soldatenkova and Christoph Zielinski and Mikl{\'o}s Wenczl},
  journal={Lung cancer},
  year={2006},
  volume={52 2},
  pages={155-63}
}
PURPOSE The primary objective of this randomized phase III study was to show significant difference in median time to progression (TTP) in patients with advanced NSCLC treated with single-agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first-line therapy. PATIENTS AND METHODS Chemonaive patients with stage IIIB/IV NSCLC received gemcitabine 1,250 mg/m(2) (days 1 and 8) plus cisplatin 80 mg/m(2) (day 1) every 21 days. Patients… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Connections & Topics

Mentioned Connections BETA
Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized ( 2:1 fashion ) to receive maintenance gemcitabine ( 1,250 mg / m(2 ) on days 1 and 8 every 21 days ) plus best supportive care ( GEM arm ) , or best supportive care only ( BSC arm ) . RESULTS .
Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized ( 2:1 fashion ) to receive maintenance gemcitabine ( 1,250 mg / m(2 ) on days 1 and 8 every 21 days ) plus best supportive care ( GEM arm ) , or best supportive care only ( BSC arm ) . RESULTS .
Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized ( 2:1 fashion ) to receive maintenance gemcitabine ( 1,250 mg / m(2 ) on days 1 and 8 every 21 days ) plus best supportive care ( GEM arm ) , or best supportive care only ( BSC arm ) . RESULTS .
The primary objective of this randomized phase III study was to show significant difference in median time to progression ( TTP ) in patients with advanced NSCLC treated with single - agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first - line therapy .
The primary objective of this randomized phase III study was to show significant difference in median time to progression ( TTP ) in patients with advanced NSCLC treated with single - agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first - line therapy .
Maintenance therapy with gemcitabine , following initial therapy with gemcitabine plus cisplatin , was feasible , and produced significantly longer TTP compared to best supportive care alone .
Maintenance therapy with gemcitabine , following initial therapy with gemcitabine plus cisplatin , was feasible , and produced significantly longer TTP compared to best supportive care alone .
Chemonaive patients with stage IIIB / IV NSCLC received gemcitabine 1,250 mg / m(2 ) ( days 1 and 8) plus cisplatin 80 mg / m(2 ) ( day 1 ) every 21 days .
Cisplatin and gemcitabine first - line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non - small cell lung cancer : a phase III trial .
Cisplatin and gemcitabine first - line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non - small cell lung cancer : a phase III trial .
Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized ( 2:1 fashion ) to receive maintenance gemcitabine ( 1,250 mg / m(2 ) on days 1 and 8 every 21 days ) plus best supportive care ( GEM arm ) , or best supportive care only ( BSC arm ) . RESULTS .
Chemonaive patients with stage IIIB / IV NSCLC received gemcitabine 1,250 mg / m(2 ) ( days 1 and 8) plus cisplatin 80 mg / m(2 ) ( day 1 ) every 21 days .
The primary objective of this randomized phase III study was to show significant difference in median time to progression ( TTP ) in patients with advanced NSCLC treated with single - agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first - line therapy .
Maintenance therapy with gemcitabine , following initial therapy with gemcitabine plus cisplatin , was feasible , and produced significantly longer TTP compared to best supportive care alone .
The primary objective of this randomized phase III study was to show significant difference in median time to progression ( TTP ) in patients with advanced NSCLC treated with single - agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first - line therapy .
Cisplatin and gemcitabine first - line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non - small cell lung cancer : a phase III trial .
Maintenance therapy with gemcitabine , following initial therapy with gemcitabine plus cisplatin , was feasible , and produced significantly longer TTP compared to best supportive care alone .
Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized ( 2:1 fashion ) to receive maintenance gemcitabine ( 1,250 mg / m(2 ) on days 1 and 8 every 21 days ) plus best supportive care ( GEM arm ) , or best supportive care only ( BSC arm ) . RESULTS .
Cisplatin and gemcitabine first - line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non - small cell lung cancer : a phase III trial .
Patients achieving objective response or disease stabilization following initial gemcitabine plus cisplatin therapy were randomized ( 2:1 fashion ) to receive maintenance gemcitabine ( 1,250 mg / m(2 ) on days 1 and 8 every 21 days ) plus best supportive care ( GEM arm ) , or best supportive care only ( BSC arm ) . RESULTS .
All Topics